Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F12%3A11588" target="_blank" >RIV/00216208:11110/12:11588 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/12:11588

Result on the web

<a href="http://dx.doi.org/10.1016/S0140-6736(12)61768-1" target="_blank" >http://dx.doi.org/10.1016/S0140-6736(12)61768-1</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Original language description

Background The anti-CD52 monoclonal antibody alemtuzumab reduces disease activity in previously untreated patients with relapsing-remitting multiple sclerosis. We aimed to assess efficacy and safety of alemtuzumab compared with interferon beta 1a in patients who have relapsed despite first-line treatment. Methods In our 2 year, rater-masked, randomised controlled phase 3 trial, we enrolled adults aged 18-55 years with relapsing-remitting multiple sclerosis and at least one relapse on interferon beta orglatiramer. Eligible participants were randomly allocated in a 1: 2: 2 ratio by an interactive voice response system, stratified by site, to receive subcutaneous interferon beta 1a 44 mu g, intravenous alemtuzumab 12 mg per day, or intravenous alemtuzumab 24 mg per day. Interferon beta 1a was given three-times per week and alemtuzumab was given once per day for 5 days at baseline and for 3 days at 12 months. The 24 mg per day group was discontinued to aid recruitment, but data are includ

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FH - Neurology, neuro-surgery, nuero-sciences

OECD FORD branch

—

Project

—

Continuities

Z - Vyzkumny zamer (s odkazem do CEZ)

Publication year

2012

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lancet

ISSN

0140-6736

e-ISSN

—

Volume of the periodical

380

Issue of the periodical within the volume

9856

Country of publishing house

GB - UNITED KINGDOM

Number of pages

11

Pages from-to

1829-1839

UT code for WoS article

000311435000028

EID of the result in the Scopus database

—